(1992) described the IGF-1 LR3 analog and documented its dramatically reduced IGFBP binding compared to native IGF-1, establishing the pharmacokinetic rationale for its use as a research tool (PMID 1601853)
You'll need these to wipe the vial stoppers
14 Current assays have limited capacity to distinguish among distinct resistance pathways, such as target mutations, bypass pathway activation, or phenotypic transitions
Contraindications: Lifestyle Factors Complementary strategies for optimal outcomes
The question I always have is if I treated 100 people with concussion or 100 people with long Covid, would the response rate be 35 to 40 percent, in which case, wow, this is really useful as a medicine, or 3 percent? Health institutions must figure out how to harness the data the great GLP-1 experiment is yielding